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In view of the availability of drugs that may slow or even halt
the progression of Alzheimer’s disease (AD), the possibility
to routinely discriminate individuals carrying incipient AD
is utmost important. The CSF biomarkers beta-amyloid and
tau are increasingly used in several countries in Europe for
their high diagnostic accuracy in detecting early or even
prodromal AD. Up till now, thousands of subjects have been
studiedeitherinresearchorroutinesetting,givingsensitivity
and speciﬁcity values invariably above 80%. Despite these
clinically relevant results, CSF analysis is still considered only
a supportive exam in AD diagnostic work-up. We think
there is a great need to improve the medical awareness
about the importance to perform lumbar puncture as a
routine procedure in the diagnostic assessment of cognitive
deterioration.
In line with this belief, the ﬁrst paper of this special issue
addresses the usefulness of cerebrospinal ﬂuid analysis for
diagnosticdeﬁnitionofcognitivedeﬁcits,andthesecondone
further focuses on the ethical issues related to early diagnosis
of Alzheimer’s disease. As a corollary, the third paper reports
some reﬂections about the actual need in clinical practice of
guidelines for diagnosis and management of incipient AD.
The fourth paper illustrates what is known about CSF
biomarkers for diagnosing AD, and the ﬁfth paper gives a
diﬀerent perspective according to the Canadian guidelines
for dementia diagnosis. An up-dated and comprehensive
view of crucial issues emerged from large multicentre studies
(which have clearly highlighted the inter-centre variability of
these determinations) on CSF biomarkers for AD diagnosis
is reported in the sixth paper. Accordingly, the seventh
paper nicely describes the eﬀorts done for standardization
of assay procedures and the eighth paper further goes
into details about the many factors inducing variation
of amyloid beta concentration, which heavily hampers, at
present, a good inter-centre reliability. Besides the state
of art about what is known on classical CSF biomarkers
for early diagnosis in routine clinical practice, there also
are impressive international research initiatives aimed at
identifying new biomarkers for neurodegenerative diseases.
This issue is thoroughly addressed by the ninth paper, which
gives an overview of the EU-funded consortium cNEUPRO.
The issue of the role of CSF biomarkers in non-AD
dementias is also partly addressed in this special issue. An
overview on CSF biomarkers in dementia with Lewy bodies
(DLB) is given in the tenth paper, and in the eleventh
paper the discriminative power of classical and putative CSF
biomarkers for diﬀerentiating AD, DLB, and Parkinson’s
disease with dementia (PDD) is accurately described; ﬁnally,
the usefulness of classical CSF biomarkers in characterizing
CADASIL, a genetic model of subcortical vascular dementia,
is also reported.
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TuulaPirttil¨ aI nM e mo riam
Professor Tuula Pirttil¨ a from University of Eastern Finland,
Kuopio, Finland, passed away on March 24, 2010. She was
ﬁghting against cancer for almost ﬁve years. Despite of2 International Journal of Alzheimer’s Disease
her disease, she was constantly working as clinical doctor,
scientist, and teacher.
Tuula Pirttil¨ a was born in Kuopio. She studied Medicine
at the University of Tampere and got her M.D. in 1983. She
completed her residency in neurology in 1990 and got the
degree of PhD three years later. After that, she moved to New
York, USA and as post doc she carried out doing studies
on biomarkers of Alzheimer’s disease. She was nominated
as docent in neurology at the University of Tampere in
1995. She then returned to Kuopio as associate professor
of Neurology in 1997 and was nominated full professor of
neurology in 2005.
People who have been working with her, remember her
as an excellent clinician, teacher and scientist. Ethical issues
were very important for her. She served many years as a
chairperson of the Ethical Committee of Kuopio University
Hospital. Tuula was also an active performer in patient
organisations and in Finnish Alzheimer Research Society.
Among many other things she was also chairperson in the
working group deﬁning national and European guidelines
for diagnosis of Alzheimer disease. Her contribution to the
science was mainly focused on biomarkers. She could use
excellent material collected in Kuopio Finland including
plasma, serum, CSF samples from patients with neurodegen-
erative diseases, especially Alzheimer’s disease. Her group set
up a service laboratory at the University of Eastern Finland
that is currently serving the whole country. Her contribution
to the EU funded cNEUPRO Consortium has been decisive
for the success of the initiative, and she gave her enthusiastic
contribution until she could.
Tuula showed unbelievable talent and wisdom. She will
berememberedasaverywarmandethusiasticperson,always
availabletolistenandengage,andhersmilesandlaughswere
contagious.
All of us who had the privilege to work with her are
missing a great person, scientist, teacher and clinician.
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